Brevital en es it fr

Brevital Brand names, Brevital Analogs

Brevital Brand Names Mixture

  • No information avaliable

Brevital Chemical_Formula

C14H18N2O3

Brevital RX_link

http://www.rxlist.com/cgi/generic3/methohexital.htm

Brevital fda sheet

Brevital FDA

Brevital msds (material safety sheet)

Brevital Synthesis Reference

No information avaliable

Brevital Molecular Weight

262.304 g/mol

Brevital Melting Point

No information avaliable

Brevital H2O Solubility

No information avaliable

Brevital State

Solid

Brevital LogP

1.724

Brevital Dosage Forms

Powder for solution

Brevital Indication

Indicated for use as an intravenous anaesthetic.

Brevital Pharmacology

Methohexital, a barbiturate, is used for the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation.

Brevital Absorption

The absolute bioavailability following rectal administration of methohexital is 17%.

Brevital side effects and Toxicity

The onset of toxicity following an overdose of intravenously administered methohexital will be within seconds of the infusion. If methohexital is administered rectally or is ingested, the onset of toxicity may be delayed. The manifestations of an ultrashort-acting barbiturate in overdose include central nervous system depression, respiratory depression, hypotension, loss of peripheral vascular resistance, and muscular hyperactivity ranging from twitching to convulsive-like movements. Other findings may include convulsions and allergic reactions. Following massive exposure to any barbiturate, pulmonary edema, circulatory collapse with loss of peripheral vascular tone, and cardiac arrest may occur.

Brevital Patient Information

When appropriate, patients should be instructed as to the hazards of drowsiness that may follow use of barbiturates. Outpatients should be released in the company of another individual, and no skilled activities, such as operating machinery or driving a motor vehicle, should be engaged in for 8 to 12 hours.

Brevital Organisms Affected

Humans and other mammals